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Abstract
Background: The United Republic of Tanzania is one of the 22 high M. tuberculosis burden
countries. Data collected between 2002 and 2007 indicate that the global prevalence of drug-
resistant M. tuberculosis including MDR vary greatly. The varied drug-resistance patterns make
continuous surveillance of drug resistance an essential component of tuberculosis control program.
Findings:  M. tuberculosis isolates were obtained from consenting adult tuberculosis patients
involved in a placebo-controlled study to evaluate the efficacy of multivitamin supplements on
response to anti-Tb treatment in Dar es Salaam, Tanzania. Antimicrobial susceptibility testing was
done on four antimicrobial agents namely streptomycin, isoniazid, ethambutol and rifampicin. HIV
testing and CD4+ T lymphocytes enumeration were also done. A total of 280 M. tuberculosis
isolates from 191 (68%) males and 89 (32%) female patients with no previous history of anti-
tuberculosis treatment exceeding 4 weeks in the previous 12 months were tested. Among these,
133 (47%) patients were HIV seropositive. Fourteen (5.0%) isolates were resistant to any of the
anti-tuberculosis drugs. The prevalence of primary resistance was 5.0%, 0.7%, 0.4% and 0% for
isoniazid, streptomycin, rifampicin and ethambutol respectively. One isolate (0.4%) was MDR, with
resistance to isoniazid, streptomycin and rifampicin.
Conclusion: M. Tb primary resistance rate in a selected population in Dar es Salaam Tanzania is
low and efforts should be undertaken to support the Tuberculosis program.
Published: 31 July 2008
BMC Research Notes 2008, 1:58 doi:10.1186/1756-0500-1-58
Received: 13 May 2008
Accepted: 31 July 2008
This article is available from: http://www.biomedcentral.com/1756-0500/1/58
© 2008 Urassa et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Research Notes 2008, 1:58 http://www.biomedcentral.com/1756-0500/1/58
Page 2 of 5
(page number not for citation purposes)
Background
Tuberculosis (Tb) remains the world's leading cause of
death from a single infectious disease and is often the first
indicator of human immunodeficiency virus infection [1-
4]. The World Health Organization (WHO) has estimated
that one third of the world population is infected with
Mycobacterium tuberculosis (M. Tb) and the estimated inci-
dence of Tb in 2002 was 8.8 million patients of whom 3.9
million had positive smear and/or culture results [4]. Fac-
tors associated with the emergence of multi-drug resistant
tuberculosis (MDR-Tb) and their effects on the epidemiol-
ogy of Tb are complex and multifaceted and include inad-
equate treatment, irregular drug supply, inappropriate
regimens and poor patient compliance.
Primary resistance to anti-Tb drugs occurs when a patient
is infected with wild type M. Tb which is resistant to anti-
Tb drugs. Acquired resistance to anti-Tb drugs occurs
when a patient is infected with susceptible forms of M. Tb
which become resistant during treatment. Much higher
rates of primary resistance have been observed in HIV-
infected patients [2]. The WHO/IUATLD Global Project
on Drug Resistance surveillance has produced reliable and
accurate data on M. Tb resistance [3,4]. MDR in M. Tb has
been defined as resistance to at least isoniazid and
rifampicin and cure rates of patients with MDR-Tb are low
[2]. Hot spots for MDR include States of the former Soviet
Union and China but MDR has been reported in several
other countries [2,5-8].
The prevalence of resistance to anti-Tb drugs shows
marked geographical differences and has important
implications on the selection of an appropriate initial
treatment regimen. Global data on anti-Tb resistance indi-
cate a median primary resistance to at least one drug of
9.9%; with 6.5% resistance to streptomycin, 1.8% to
rifampicin, 1.0% to ethambutol while that of primary
MDR was 1.4% [1]. Recent (2002–2007) global WHO
data covering 114 countries including Tanzania and 2 spe-
cial administered regions of China has shown a global
prevalence of primary drug-resistant M. tuberculosis of
between 0% in two Western European countries to 56.3%
in Baku, Azerbaijan while the prevalence of MDR ranged
from 0% in eight countries to 19.4 and 22.3% in Republic
of Moldova and Baku, Azerbaijan respectively [4]. Several
studies done in Europe, Middle East and Asia since the
late 1990's and early 2000 have shown varied prevalence
of resistance to anti Tb drugs [9-12]. Data from several
African countries including Malawi, Burundi, S. Africa,
Central African Republic and Kenya suggest that M. Tb
resistance is of public health importance with an MDR
rate ranging from 1.4% to 11.6% [4,6,13-16].
In the era of HIV/AIDS, Tanzania has reported a three-fold
increase in notification of Tb and a two-fold increase of
new sputum smear-positive tuberculosis [17]. When stud-
ying M. Tb isolates collected in Dar es Salaam between
1992 and 1993, Yang et al reported a prevalence of resist-
ance to a single anti-Tb drug of 8.8% while 3.2% of iso-
lates were resistant to more than one drug [18]. In a study
by Chum et al, conducted between 1991 and 1993 in Tan-
zania, the overall prevalence of anti Tb drug resistance was
6.2%, while primary resistance was 4% in HIV-seroposi-
tive and 5.8% in HIV-seronegative patients; acquired
resistance was 19% [19]. The recently published WHO
report has shown that among 369 new M Tb isolates col-
lected in 2007, overall resistance to any of the anti Tb drug
was 6.2% while the MDR rate was 1.1% [4]. Here we
report on the prevalence of primary resistance of M. Tb to
various anti-Tb drugs in Dar es Salaam Tanzania. Tb iso-
lates for this study were collected from HIV seropositive
and HIV seronegative patients between 2001 and 2004.
Methods
Patients attending five of the 14 out-patient Tb treatment
clinics in Dar es Salaam, Tanzania were invited to partici-
pate in a placebo-controlled study to evaluate the efficacy
of multivitamin supplements on response to anti-Tb treat-
ment. Detailed methodology of the study population has
been described elsewhere [20,21]. In brief, participants in
the trial were men and women aged 18 to 65 years, who
had at least two positive sputum smears and who
intended to stay in Dar es Salaam for at least 18 months
after the completion of Tb therapy. Subjects provided
written informed consent to participate in the study. Sub-
jects with Karnofsky scores less than 40% or haemoglobin
less than 7.0 gm/dL were excluded from the main study
because it was thought that they would not be able to
demonstrate significant benefit from the micronutrients.
Furthermore, patients with a history of previous Tb treat-
ment exceeding four weeks during the last 12 months or
pregnant women were excluded from the study. The spu-
tum samples from patients fulfilling the recruitment crite-
ria were inoculated into Lowenstein Jensen medium and
incubated at 37°C for 2–4 weeks. M. Tb colonies were
identified based on typical microscopical appearance on
Auramine Rhodamine fluorescent stained smears and typ-
ical morphology on Lowenstein Jensen medium. Antimi-
crobial susceptibility testing to isoniazid, streptomycin,
rifampicin and ethambutol was done using the propor-
tional method.
Following pretest counselling, blood samples were
obtained and tested for presence of HIV antibodies using
two sequential ELISAs (Enzygnost anti HIV 1+2 Behring
(Marburg, Germany) followed by Wellcozyme Recom-
binant anti HIV 1 (Murex Biotech Ltd, Dart-ford, UK) in
an alternative confirmatory strategy [22]. Samples with
discrepant results were retested using Western blot
(Genetic System, Redmond, WA), which was interpretedBMC Research Notes 2008, 1:58 http://www.biomedcentral.com/1756-0500/1/58
Page 3 of 5
(page number not for citation purposes)
according to WHO criteria [23]. After the results, the
patients were post-test counselled and those who were
HIV infected were managed according to prevailing
national guidelines as anti-retroviral drugs were not avail-
able in Tanzania during the study period. Lymphocyte
subsets were determined using flow cytometry. Analyses
were conducted using the Statistical Package for Social Sci-
entists (SPSS 12.0; Norusis, SPSS Inc., Chicago, IL, USA).
Proportions were compared using Chi square tests. Com-
parison of means was done using unpaired t-test. A two-
sided p-value of less than 0.05 was considered as statisti-
cally significant.
The study protocol was approved by ethical committees in
Muhimbili University of Health and Allied Sciences and
Harvard School of Public Health. All patients were treated
following national guidelines of management of tubercu-
losis and HIV infections prevailing during the study
period.
The study population
A total of 887 Tb patients living in Dar es salaam, Tanza-
nia were enrolled in the trial, of which 590 (67%) were
males and 297 (33%) females. Among these, 416 (47%)
were HIV seronegative while 471 (53%) were HIV-1 sero-
positive. Of the 887 patients enrolled, sputum culture and
sensitivity testing was done on 722 (81%) patients.
Among these, sputum culture and sensitivity testing for
280 patients was done between the date of recruitment
into the study and one month of starting anti-Tb treat-
ment while for the remaining 442 patients, it was done
after the first month of starting anti-Tb treatment. The
data from the later group of patients were not included in
the current analysis because participants had taken the
anti-Tb drugs for some time before sputum collection
which can influence the antimicrobial susceptibility pat-
tern of the M Tb isolates. There were no significant differ-
ences in the mean age or sex distribution between the
patients enrolled in the main study (887), those who had
culture results (722) and those who had culture and sen-
sitivity results during the first month of treatment (280).
However, the proportion of HIV seropositive patients was
significantly lower among participants with culture data
compared to the total study population.
Antimicrobial resistance
Among the 280 M. Tb isolates, 191 (68%) and 89 (32%)
were obtained from males and female patients respec-
tively. The mean (median, SD) age of the patients was 32
years (31.0, 8) and 32.0 years (29.0, 9) for males and
females respectively (p = 0.48). One hundred forty seven
(53%) isolates were obtained from HIV seronegative
patients while 133 (47%) were obtained from HIV serop-
ositive patients. Among the HIV seropositive patients, 44
(39%) had CD4+ T lymphocytes ranging from 0 to 199/
μL, 47 (42%) from 200–499/μL and 22 (19%) had CD4+
T lymphocytes 500/μL or more. For 20 (15%) patients we
did not have CD4 data at recruitment.
Table 1 shows the resistance pattern of the M. Tb isolates.
Among the 280 M. Tb isolates tested, 14 were resistant to
at least one of the anti-Tb drugs and of these eight isolates
were from HIV seropositive patients while 6 were from
HIV seronegative patients; four isolates were from females
and 10 were from males. The MDR isolate was from an
HIV-seropositive patient with 641 CD4+ T lymphocytes/
μL living in Dar es Salaam during the study period
The primary anti-Tb resistance pattern in the current study
is similar to that of another Tanzanian study done
between 1991 and 1993 with a primary mono-resistance
rate of 0.3% to rifampicin and an MDR prevalence of
0.4% [19]. In addition our findings are similar to the
recent primary resistance rates of M Tb isolates collected
in Tanzania in 2007 which were reported by WHO [4].
However these resistance rates are low in comparison to
the global summary by Pablos-Mendez et al which
reported a median primary resistance of 9.9% to any of
the anti-Tb drugs and an MDR of 1.4% [1], and are also
similar to reports from Burundi, South Africa and Kenya
[13,14,16].
Most published M. Tb resistance reports tend to combine
results obtained from patients who are treated for the first
time and those with history of previous anti Tb treatment.
Globally, acquired resistance figures are much higher
compared to primary resistance. Our data was based on
patients with no history of use of anti-Tb drugs exceeding
4 weeks in the previous 12 months and therefore, may not
reflect the prevalence of acquired resistance [1]. There are
published reports suggesting that the HIV pandemic and
Table 1: The antimicrobial susceptibility pattern of the M tuberculosis isolates.
Resistance to
Isoniazid Streptomycin Rifampicin Ethambutol Any MDR
N 14/280 2/280 1/280 0 14/280 1/280
% 5.0 0.7 0.4 0 5.0 0.4BMC Research Notes 2008, 1:58 http://www.biomedcentral.com/1756-0500/1/58
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Tb epidemic are concurrently fuelling each other and may
be associated with increased resistance to anti-Tb drugs
[2]. In the current study there was no evidence pointing to
increased resistance in HIV-seropositive patients, proba-
bly due to the low prevalence of the resistant strains and
also because only primary resistance was analysed as com-
pared to acquired resistance.
One major limitation in the current analysis is the exclu-
sion of patients with a Karnofsky score of less than 40%
which resulted in exclusion of patients with more severe
disease and possibly those with resistant strains including
MDR and X-MDR which is however more common in
acquired compared to primary resistance.
Conclusion
The M. Tb primary resistance rate in this selected popula-
tion in Dar es Salaam Tanzania is low and efforts should
be undertaken to support the Tuberculosis program and
conduct further studies in order to guide treatment of M
Tb patients in Tanzania.
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